Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

STM-02: Phase I Study of IGF-Methotrexate Conjugate in the Treatment of Advanced Tumors Expressing Insulin-like Growth Factor Receptor 1 (IGF-1R)

NCT02045368 is registered in ClinicalTrials.gov with IGF Oncology, LLC as lead sponsor.

NCT NCT02045368
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02045368 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
STM-02: Phase I Study of IGF-Methotrexate Conjugate in the Treatment of Advanced Tumors Expressing Insulin-like Growth Factor Receptor 1 (IGF-1R)
Lead sponsor
IGF Oncology, LLC
Phase
Phase 1
Overall status
Completed
Start date
January 28, 2014
Completion date
September 30, 2016
Enrollment
92 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

brain cancer, breast cancer, gastrointestinal cancers, genitourinary cancers, gynecologic cancers, head and neck cancers, melanoma, thoracic cancers